Phathom Pharmaceuticals (PHAT) Current Assets (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Current Assets data on file, last reported at $276.6 million in Q1 2026.

• On a quarterly basis, Current Assets rose 4.41% year-over-year to $276.6 million in Q1 2026; TTM through Mar 2026 was $276.6 million, a 4.41% increase from a year earlier, with the FY2025 full-year figure at $229.0 million, down 36.42% from the prior year.
• Current Assets for Q1 2026 stood at $276.6 million, up from $229.0 million in the prior quarter.
• Over the last five years, Current Assets for PHAT reached as high as $397.4 million in Q4 2023 and fell as low as $139.8 million in Q1 2023.
• Historically, Current Assets has averaged $253.6 million across 5 years, with a median of $229.0 million in 2025.
• Across the five-year window, Current Assets jumped 147.6% in 2023 and plunged 44.42% in 2025, its largest moves.
• Year by year, Current Assets stood at $160.5 million in 2022, then jumped by 147.6% to $397.4 million in 2023, then retreated by 9.38% to $360.1 million in 2024, then plunged by 36.42% to $229.0 million in 2025, then gained by 20.79% to $276.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $276.6 million in Q1 2026, $229.0 million in Q4 2025, and $207.8 million in Q3 2025.